Announcement • Apr 10
Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited. Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited on April 8, 2026. The acquisition strengthens Getinge’s offering to endoscopy units across the United Kingdom (UK) by combining Pennamed’s established consumables portfolio and strong customer relationships with Getinge’s expertise in endoscope reprocessing, infection control, and washer-disinfector technology.
Getinge and Pennamed has combined 350 employees.
Abi Godfrey, Alex Parry and Matt Harvey of Grant Thornton UK LLP acted as accountants for Pennamed Limited. Emma Orriss and Nigel Beckwith of Gosschalks LLP acted as legal advisors for Pennamed Limited. Covington & Burling Llp acted as legal advisor and Ernst & Young AB acted as accountant for Getinge AB.
Getinge AB (publ) (OM:GETI B) completed the acquisition of Pennamed Limited on April 8, 2026. Announcement • Mar 12
Getinge AB (publ) Announces Malin Persson Declines Re-Election as Board Member, Effective April 21, 2026 Getinge AB (publ) at its Annual General Meeting to be held on April 21, 2026, announced Malin Persson has declined re-election as board member. Announcement • Jan 28
Getinge AB (publ), Annual General Meeting, Apr 21, 2026 Getinge AB (publ), Annual General Meeting, Apr 21, 2026. Announcement • Jan 27
Getinge AB (Publ) Proposes Dividend Getinge AB (publ) announced the proposal of dividend per share of SEK 4.75 (4.60). Announcement • Dec 19
Getinge AB Announces Malin Persson Declines Re-Election to the Board Getinge AB announced that Malin Persson, a board member since 2014, has announced that she will not be available for re-election to the board in 2026. Announcement • Oct 21
Getinge AB (Publ) Reaffirms Earnings Guidance for the Year 2025 Getinge AB (publ) reaffirmed earnings guidance for the year 2025. The company remain with expectation for organic net sales growth to be in the range of 2% to 5% and long-term financial target of over 12% EPS growth is also intact despite the headwind from tariffs and currency. Announcement • Jul 02
Getinge AB (publ)(OM:GETI B) dropped from OMX Stockholm 30 Index Getinge AB (publ) has been dropped from the OMX OMX Stockholm 30 Index Announcement • Mar 18
Getinge Introduces Neural Pressure Support for the Servo-U Ventilator System Getinge announces the launch of its latest innovation in ICU ventilation – Neural Pressure Support (NPS) – available for both invasive and non-invasive ventilation. Building on its most personalized ventilation modes, NAVA and NIV NAVA, these two new NPS modes offer clinicians more options to provide personalized ventilation that aims to protect both the lungs and diaphragm. For years, Getinge has been market-driving when it comes to developing first-of-its-kind intensive care ventilation modes. The medtech company is introducing NPS and NIV NPS to widen its neurally controlled ventilation offering. The new Neural Pressure Support modes give clinicians the opportunity to deliver classical pressure support ventilation, enhanced with neural trigger and breath termination in synchrony with diaphragmatic muscle activity. This may be particularly beneficial for complex and challenging ICU patient groups, such as obstructive COPD patients requiring instant synchronization and fast pressurization, and restrictive ARDS patients with stiff lungs and an excessive respiratory drive. Announcement • Jan 29
Getinge AB (publ), Annual General Meeting, Apr 22, 2025 Getinge AB (publ), Annual General Meeting, Apr 22, 2025. Location: halmstad Sweden Announcement • Jan 28
Getinge AB (publ) Provides Organic Sales Guidance for the Year 2025 Getinge AB (publ) provided organic sales guidance for the year 2025. The company have a positive outlook on 2025 and expect organic sales growth of 2%-5% for the full year 2025. Announcement • Nov 28
Getinge AB (Publ) Announces Changes of the Nomination Committee Getinge AB (publ) announced that the composition of Getinge AB (publ)'s Nomination Committee ahead of the 2025 Annual General Meeting has been updated following changed ownership structure in the company. As a consequence, Carnegie Fonder has appointed Simon Blecher as member of the Nomination Committee. This means that Getinge's Nomination Committee ahead of the 2025 Annual General Meeting comprises the company's Chairman, Johan Malmquist, and representatives from the following owners, listed by size: 1. Carl Bennet AB: Carl Bennet 2. Fourth Swedish National Pension Fund: Jannis Kitsakis 3. AMF Pension & Fonder: Dick Bergquist 4. Carnegie Fonder: Simon Blecher 5. Swedbank Robur: Marianne Nilsson. Announcement • Nov 09
Getinge Appoints Alexandra Holland Executive Vice President of Communications, Effective November 11, 2024 Getinge appointed Alexandra Holland as the new Executive Vice President of Communications effective November 11, 2024. Alexandra will become a member of the Getinge Executive Team and lead the development, advancement, and execution of the company's communications and public affairs strategy. Alexandra has dedicated her career to healthcare, including almost 15 years at Johnson & Johnson in the consumer, corporate, and medtech sectors. Most recently, Alexandra served as Vice President, Business and Culture Communications, MedTech, responsible for championing key initiatives to improve and protect reputation, drive business results, advance culture, and deliver value to patients, customers and shareholders. Alexandra Holland will report to Mattias Perjos and be a member of Getinge's executive team. She will be based in the United States and will take office on November 11th. Announcement • Sep 13
Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners. Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million on August 22, 2024. Approximately $477 million, on a cash and debt free basis, for all issued and outstanding shares, of which $253 million is payable in cash on closing. The earn-out payments are expected to be paid between 2024 and 2026 if agreed upon regulatory and financial performance milestones are achieved and may exceed $224 million in aggregate. The initial payout related to the acquisition will be financed through a bridge loan provided by SEB. In 2023, Paragonix Technologies reported revenues of $43.1 million. Upon closing, Paragonix will become a wholly owned subsidiary of Getinge.
The Boards of Directors of both Paragonix and Getinge have approved the transaction. The transaction is subject to subject to antitrust regulations and pending the satisfaction of customary closing conditions. The closing is expected to take place late Q3 or early Q4 2024.
Sheppard, Mullin, Richter & Hampton LLP is acted as legal advisor, Knobbe, Martens, Olson & Bear, LLP is acted as Intellectual Property counsel and UBS Investment Bank is acted as exclusive financial advisor to Paragonix.
Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners on September 11, 2024. All conditions for the transaction have now been fulfilled. Announcement • Aug 23
Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million. Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million on August 22, 2024. Approximately $477 million, on a cash and debt free basis, for all issued and outstanding shares, of which $253 million is payable in cash on closing. The earn-out payments are expected to be paid between 2024 and 2026 if agreed upon regulatory and financial performance milestones are achieved and may exceed $224 million in aggregate. The initial payout related to the acquisition will be financed through a bridge loan provided by SEB. In 2023, Paragonix Technologies reported revenues of $43.1 million. Upon closing, Paragonix will become a wholly owned subsidiary of Getinge.
The Boards of Directors of both Paragonix and Getinge have approved the transaction. The transaction is subject to subject to antitrust regulations and pending the satisfaction of customary closing conditions. The closing is expected to take place late Q3 or early Q4 2024.
Sheppard, Mullin, Richter & Hampton LLP is acted as legal advisor, Knobbe, Martens, Olson & Bear, LLP is acted as Intellectual Property counsel and UBS Investment Bank is acted as exclusive financial advisor to Paragonix. Announcement • Jul 01
Getinge AB (publ) to Report Q2, 2024 Results on Jul 18, 2024 Getinge AB (publ) announced that they will report Q2, 2024 results at 8:00 AM, Central European Standard Time on Jul 18, 2024 
